79 related articles for article (PubMed ID: 38503806)
1. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract][Full Text] [Related]
4. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
5. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
[TBL] [Abstract][Full Text] [Related]
8. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
9. Mantle-Cell Lymphoma.
Armitage JO; Longo DL
N Engl J Med; 2022 Jun; 386(26):2495-2506. PubMed ID: 35767440
[No Abstract] [Full Text] [Related]
10. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Campo E; Jaffe ES; Cook JR; Quintanilla-Martinez L; Swerdlow SH; Anderson KC; Brousset P; Cerroni L; de Leval L; Dirnhofer S; Dogan A; Feldman AL; Fend F; Friedberg JW; Gaulard P; Ghia P; Horwitz SM; King RL; Salles G; San-Miguel J; Seymour JF; Treon SP; Vose JM; Zucca E; Advani R; Ansell S; Au WY; Barrionuevo C; Bergsagel L; Chan WC; Cohen JI; d'Amore F; Davies A; Falini B; Ghobrial IM; Goodlad JR; Gribben JG; Hsi ED; Kahl BS; Kim WS; Kumar S; LaCasce AS; Laurent C; Lenz G; Leonard JP; Link MP; Lopez-Guillermo A; Mateos MV; Macintyre E; Melnick AM; Morschhauser F; Nakamura S; Narbaitz M; Pavlovsky A; Pileri SA; Piris M; Pro B; Rajkumar V; Rosen ST; Sander B; Sehn L; Shipp MA; Smith SM; Staudt LM; Thieblemont C; Tousseyn T; Wilson WH; Yoshino T; Zinzani PL; Dreyling M; Scott DW; Winter JN; Zelenetz AD
Blood; 2022 Sep; 140(11):1229-1253. PubMed ID: 35653592
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
12. Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
Zinzani PL; Martelli M; Ferrero S; Gentile M; Laurenti L; Romana Mauro F; Sportoletti P; Tedeschi A; Varettoni M; Visco C
Hematol Oncol; 2022 Oct; 40(4):518-527. PubMed ID: 35247223
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma patients in first relapse: we pretty much know what to do.
Quaglia FM; Visco C
Oncotarget; 2021 Aug; 12(17):1724-1726. PubMed ID: 34434500
[No Abstract] [Full Text] [Related]
14. SENP1 promotes MCL pathogenesis through regulating JAK-STAT5 pathway and SOCS2 expression.
Zhang Y; Ma Y; Wu G; Xie M; Luo C; Huang X; Tian F; Chen J; Li X
Cell Death Discov; 2021 Jul; 7(1):192. PubMed ID: 34312374
[TBL] [Abstract][Full Text] [Related]
15. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Ondrisova L; Mraz M
Front Oncol; 2020 Oct; 10():591577. PubMed ID: 33154951
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
